Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 147

1.

Serum levels of anticholinergic drugs in treatment of acute extrapyramidal side effects.

Tune L, Coyle JT.

Arch Gen Psychiatry. 1980 Mar;37(3):293-7.

PMID:
6102457
2.

Acute extrapyramidal side effects: serum levels of neuroleptics and anticholinergics.

Tune L, Coyle JT.

Psychopharmacology (Berl). 1981;75(1):9-15.

PMID:
6117922
3.

Relation of serum anticholinergicity to cognitive status in schizophrenia patients taking clozapine or risperidone.

Tracy JI, Monaco CA, Abraham G, Josiassen RC, Pollock BG.

J Clin Psychiatry. 1998 Apr;59(4):184-8.

PMID:
9590669
4.

Anticholinergic activity in the serum of patients receiving maintenance amitriptyline or doxepin therapy.

Aaltonen L, Syvälahti E, Iisalo E, Peltomäki T.

Acta Pharmacol Toxicol (Copenh). 1985 Jan;56(1):75-80.

PMID:
3976405
5.

Drug levels and antiparkinsonian drugs in neuroleptic-treated schizophrenic patients.

Hitri A, Craft RB, Sethi R, Sinha D.

Clin Neuropharmacol. 1987 Jun;10(3):261-71.

PMID:
2900683
6.

Radio receptor assay of serum neuroleptic levels in psychiatric patients.

Krska J, Sampath G, Shah A, Soni SD.

Br J Psychiatry. 1986 Feb;148:187-93.

PMID:
2870755
7.

Screening for cognitive toxicity of anticholinergic drugs.

Katz IR, Greenberg WM, Barr GA, Garbarino C, Buckley P, Smith D.

J Clin Psychiatry. 1985 Aug;46(8):323-6.

PMID:
2862135
8.
9.
10.

Serum neuroleptic levels and extrapyramidal side effects in patients treated with amoxapine.

Gaffney GR, Tune LE.

J Clin Psychiatry. 1985 Oct;46(10):428-9.

PMID:
2864332
11.

Biperiden and haloperidol plasma levels and extrapyramidal side effects in schizophrenic patients.

Meszaros K, Lenzinger E, Hornik K, Schönbeck G, Hatzinger R, Langer G, Sieghart W, Aschauer HN.

Neuropsychobiology. 1997;36(2):69-72.

PMID:
9267855
12.
13.

Tricyclic antidepressant radioreceptor assay.

Innis RB, Tune L, Rock R, Depaulo R, U'Prichard DC, Snyder SH.

Eur J Pharmacol. 1979 Oct 15;58(4):473-7.

PMID:
510379
14.
15.

Is the low incidence of extrapyramidal side-effects of antipsychotics associated with antimuscarinic properties?

Laduron PM, Leysen JE.

J Pharm Pharmacol. 1978 Feb;30(2):120-2. No abstract available.

PMID:
24098
16.

Pupillometry and radioreceptor binding. Semeiologic suggestions in the evaluation of the treatment with anticholinergic drugs.

Micieli G, Flauto C, Magri M, Vescovi A, Cavallini A, Parati E.

Arzneimittelforschung. 1990 Jun;40(6):647-50.

PMID:
2396998
17.

Anticholinergic agents for prophylaxis of neuroleptic-induced dystonic reactions: a prospective study.

Sramek JJ, Simpson GM, Morrison RL, Heiser JF.

J Clin Psychiatry. 1986 Jun;47(6):305-9.

PMID:
2872206
18.

[Plasma anticholinergic activity and cognitive function in geriatric patients].

Thienhaus OJ, Thoene J, Allen A, Zemlan FP.

Psychiatr Neurol Med Psychol (Leipz). 1990 May;42(5):275-81. German.

PMID:
1975100
19.

Neuroleptic binding to sigma receptors: possible involvement in neuroleptic-induced acute dystonia.

Jeanjean AP, Laterre EC, Maloteaux JM.

Biol Psychiatry. 1997 May 15;41(10):1010-9.

PMID:
9129781
20.

Effects of anticholinergic drug withdrawal on memory, regional cerebral blood flow and extrapyramidal side effects in schizophrenic patients.

Mori K, Yamashita H, Nagao M, Horiguchi J, Yamawaki S.

Pharmacopsychiatry. 2002 Jan;35(1):6-11.

PMID:
11819152

Supplemental Content

Support Center